A chemotherapy response classifier based on support vector machines for high-grade serous ovarian carcinoma

Chao-Yang Sun¹,* , Tie-Fen Su²,* , Na Li¹,* , Bo Zhou¹, En-Song Guo¹, Zong-Yuan Yang¹, Jing Liao¹, Dong Ding¹, Qin Xu¹, Hao Lu¹, Li Meng³, Shi-Xuan Wang¹, Jian-Feng Zhou³, Hui Xing⁴, Dan-Hui Weng¹, Ding Ma¹, Gang Chen¹

¹Department of Obstetrics and Gynaecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China
²Department of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China
³Department of Haematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China
⁴Department of Obstetrics and Gynecology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei 441021, China

*These authors contributed equally to this work

Correspondence to: Ding Ma, e-mail: dma@tjh.tjmu.edu.cn
Gang Chen, e-mail: gumpc@126.com

Keywords: ovarian cancer, chemoresistance, support vector machine

Received: August 25, 2015 Accepted: November 21, 2015 Published: December 12, 2015

ABSTRACT

Long-term outcome of high-grade serous epithelial ovarian carcinoma (HGSOC) remains poor as a result of recurrence and the emergence of drug resistance. Almost all the patients were given the same platinum-based chemotherapy after debulking surgery even though some of them are naturally resistant to the first-line chemotherapy. No method could verify this part of patients right after the surgery currently. In this study, we used 156 paraffin-embedded high-grade HGSOC specimens for immunohistochemical analysis with 37 immunology markers, and association between the expression levels of these markers and the chemoresponse were evaluated. A support vector machine (SVM)-based HGSOC prognostic classifier was then established, and was validated by a 95-patient independent cohort. The classifier was strongly predictive of chemotherapy resistance, and divided patients into low- and high-risk groups with significant differences progression-free survival (PFS) and overall survival (OS). This classifier may provide a potential way to predict the chemotherapy resistance of HGSOC right after the surgery, and then allow clinicians to make optimal clinical decision for those potentially chemoresistant patients. The potential clinical application of this classifier will benefit those patients with primary drug resistance.

INTRODUCTION

Epithelial ovarian carcinoma (EOC) is the fifth leading cause of cancer death in women [1]. The 5-year survival rates for late-stage EOC were < 10% between 2004 and 2008 [2]. Long-term outcome remains poor as a result of recurrence and the emergence of drug resistance after original debulking surgery and chemotherapy, especially for the high-grade serous epithelial ovarian carcinoma (HGSOC).

HGSOC is highly heterogeneous. Conventional prognostic features such as patient age, International Federation of Gynecology and Obstetrics (FIGO) stage, histological grade, and initial surgery results are insufficient to capture individual variations in chemoresponse and prognosis. All patients receive the same regimen regardless of their chemoresponse. Therefore, it is important to develop methods that can identify patients who may be resistant to traditional platinum-based chemotherapy and then redirect them to
alternative, potentially more efficacious, chemotherapeutic agents (e.g., topotecan) or radiation therapy [3], which may help to improve their overall survivals.

Molecular prognostic markers could potentially be represented by changes in gene copy number, mRNA and protein expression levels. For example, large-scale RNA expression profiling has been used to screen molecular markers associated with response to chemotherapy and prognosis in ovarian carcinomas [4–7]. However, mRNA expression detection generally requires fresh or frozen tissue that must be microdissected to remove associated non-tumor tissue that may attenuate the gene expression signature of the tumor. Furthermore, mRNA expression was not always correlated with protein levels [8]. In the clinical setting, immunohistochemistry (IHC) remains the most robust and widespread means to evaluate protein abundance in the neoplastic cells or stromal cells, since it only need paraffin-embedded (FFPE) tumor tissues that are routinely prepared in medical practice and are easy to store. Many studies have reported the assessment of single IHC markers for prognosis in ovarian cancer [9–13], but no consistent results have been obtained. We hypothesised that the value of prognostic predictors would be greatly enhanced by using a cluster of specific features, including multiple IHC markers. Support-vector machine (SVM) is a state-of-the-art classification algorithm that can take a small subset of highly discriminating genes to build extremely reliable cancer classifiers. This approach has not yet been applied to HGEOC. In this study, we developed a SVM-based prognostic classifier to predict the chemotherapy response of HGSOC which provides a more accurate measurement of chemotherapy response than is possible through traditional clinical means.

RESULTS

Patient characteristics and components of HGSOC-SVM classifier

Table 1 shows the demographic, clinical, and tumor characteristics of the patients in the discovery and validation cohorts. There was no significant difference in clinical or tumor characteristics between the training and validation cohorts. Moreover, we find that only the residual tumor (> 1 cm) is associated with chemotherapy resistance in validation cohort (Supplementary Table 1).

On the basis of SVM-RFE analysis of the 100 cases of the training set, the final HGSOC-SVM classifier integrated one clinicopathologic feature (optimal debunking surgery) and expression of 6 proteins, BRCA2, E-Cadherin, P53, BRCA1, p-AKT, Dicer1, as critical factors. Representative IHC staining for these six SVM-RFE selected markers in HGSOC tumor tissues is shown in Figure 1. Raw data was provided as the Supplementary Table 2.

HGSOC-SVM classifier and chemotherapy resistance of HGSOC

ROC curves for traditional clinicopathological prognostic factors, including age, and clinical stage, grade, residual tumor volume as well as each individual molecular marker and the HGSOC-SVM classifier in both the testing and validation cohorts sets, are illustrated in Figure 2. In the testing cohort (n = 56), the HGSOC-SVM classifier (AUC = 0.802) outperformed all the other individual prognostic factors (Figure 2A). The HGSOC-SVM classifier was strongly predictive of chemotherapy resistance (overall accuracy, 83.9%; sensitivity, 94.1%; specificity, 68.2%). These prognostic associations were also observed in the independent validation cohort (n = 95) (AUC = 0.776) (Figure 2B) including prediction of chemotherapy resistance (overall accuracy, 80.0%; sensitivity, 86.7%; specificity, 68.6%).

In univariate logistic analysis based on the testing cohort (Supplementary Table 3), the high-risk group based on the HGSOC-SVM classifier was highly associated with chemotherapy resistance (OR = 34.3, 95% CI: 6.35 to 185.24, P < .001). By contrast, there was no significant difference in chemotherapy resistance by age, histological grade, clinical stage, or optimal surgery. Similarly, in the validation cohort, high-risk group according to the HGSOC-SVM classifier was also the most important predictive factor for chemotherapy resistance (OR = 14.18, 95% CI: 5.05 to 39.77, P < .001) (Supplementary Table 3).

HGSOC-SVM classifier and HGSOC OS and PFS

In the 56 testing patients, HGSOC-SVM classifier defined 39 patients as low risk and 17 patients as high risk. OS differed significantly between low- and high-risk patients (median OS: 50.0 months, 95%CI: 41.8 to 53.5 months vs. 27 months, 95%CI: 19.5 to 35.2 months, P < .001) (Figure 3A). In the validation cohort of 95 patients, the HGSOC-SVM classifier was used to define 63 patients as low risk and 32 patients as high risk. Again, the OS differed strikingly between low- and high-risk patients (P = 0.017) (Figure 3B). PFS differed significantly between low- and high-risk patients in both the 56 testing patients (median PFS: 24.0 months, 95% CI: 19.1 to 28.9 months vs. median PFS: 11 months, 95% CI: 6.2 to 15.8 months, P < .001) (Figure 3C) and 95 patients of the independent validation cohort (median PFS: 23.0 months, 95% CI: 16.4 to 29.6 months vs. median PFS: 14 months, 95% CI: 11.8 to 16.2 months, P < .001) (Figure 3D). Univariate associations of the HGSOC-SVM classifier, clinicopathological parameters, and expression of each of the 6 immunological markers with OS and PFS in the 56 testing patients and in the 95 patients from validation cohort are shown in Tables 2 and 3. Only the
Table 1: Clinicopathological characteristics of ovarian cancer patients in training and validation cohorts

| Variables               | Total N = 251 | Training n = 100 | Validation n = 56 | Independent cohort n = 95 | P value |
|-------------------------|---------------|-----------------|------------------|---------------------------|---------|
| **Age**                 |               |                 |                  |                           |         |
| mean (SD)               | 50.7 (9.7)    | 51.3 (9.4)      | 51.3 (9.3)       | 49.2 (10.2)               | 0.171   |
| **Stage**               |               |                 |                  |                           |         |
| IIIC                    | 213           | 85 (85.0)       | 44 (78.6)        | 84 (88.4)                 | 0.264   |
| IV                      | 38            | 15 (15.0)       | 12 (21.4)        | 11 (11.6)                 |         |
| **Grade**               |               |                 |                  |                           |         |
| moderate                | 77            | 30 (30.0)       | 19 (33.9)        | 28 (29.5)                 | 0.833   |
| low                     | 174           | 70 (70.0)       | 37 (66.1)        | 67 (70.5)                 |         |
| **Residual tumor**      |               |                 |                  |                           |         |
| ≤ 1 cm                  | 167           | 63 (63.0)       | 38 (67.9)        | 66 (69.5)                 | 0.615   |
| > 1 cm                  | 84            | 37 (37.0)       | 18 (32.1)        | 29 (30.5)                 |         |
| **Chemotherapy response** |             |                 |                  |                           |         |
| sensitive               | 151           | 57 (57.0)       | 34 (60.7)        | 60 (63.2)                 | 0.677   |
| resistant               | 100           | 43 (43.0)       | 22 (39.3)        | 35 (36.8)                 |         |

Chemotherapy response was defined as relapse or progression within 6 months or later than 6 months from the last platinum-based chemotherapy, respectively.

![Image of IHC staining for selected markers](image)

**Figure 1: Representative IHC staining for these six SVM-RFE–selected markers in HGSOC tumor tissues.** The scores of staining intensity and pattern of staining of these representative images were showed in a format as A*B. A refers to the scores of staining intensity, while B represents the scores of pattern of staining. And the aggregate scores will be the scores of tumor-cell staining multiplied by the score of staining intensity.
Figure 2: Receiver operating characteristic (ROC) curves for traditional clinicopathological prognostic factors, including age, and clinical stage, grade, residual tumor volume, as well as each 6 selected molecular marker and the HGSOC-SVM classifier in both of testing and validation cohort. (A) ROC curves for 56 testing patients in discovery cohort; (B) ROC curves for 95 patients in validation cohort.
HGSOC-SVM classifier showed significant association with OS in both groups (HR = 3.90, 95% CI: 1.87 to 8.16, \( P < .001 \); and HR = 1.92, 95% CI: 1.10 to 3.34, \( P = 0.022 \), respectively). Similarly, only the HGSOC-SVM classifier had consistent statistically significant prognostic value for PFS in both groups (HR = 2.92, 95% CI: 1.55 to 5.50, \( P < .001 \) and HR = 2.38, 95% CI: 1.45 to 3.91, \( P < .001 \), respectively).

**DISCUSSION**

Identification of patients with likely chemoresistant before the commencement chemotherapy would greatly aid clinical management. Traditionally, clinical factors such as age and tumor grade have been used to assess prognosis, however they have poor predictive power [14, 15]. Immunological biomarkers may have superior prediction capacity. Many studies have reported the value of single prognostic immunomarkers in ovarian cancer, but no consistent results have been obtained [9–13].

To improve the prognostic predictive value of individual genes, supervised methods, such as decision trees, artificial neural network, could be used to combine independently informative markers to improve predict values [16–18]. SVM is one of the most classic supervised learning algorithms, useful for recognizing subtle patterns in complex datasets. The algorithm performs discriminative classification, learning by example to predict the classifications of previously unclassified patients.

![Figure 3: Kaplan-Meier OS and PFS estimate for low- and high-risk patients with HGSOC as defined by HGSOC-SVM classifier from both training and validation cohorts.](image)

(A) Kaplan-Meier OS curves for 56 testing patients in discovery cohort; (B) Kaplan-Meier OS curves for 95 patients in validation cohort; (C) Kaplan-Meier PFS curves for 56 testing patients in discovery cohort; (D) Kaplan-Meier PFS curves for 95 patients in validation cohort. Log-rank test used to calculate \( P \) values.
Table 2: Association between SVM model and clinicopathological characteristics of ovarian cancer patients and OS in testing patients of discovery cohort and in validation cohort

| Variables                      | Testing patients | Validation cohort |
|-------------------------------|------------------|-------------------|
|                               | HR (95% CI)      | P value           | HR (95% CI)      | P value           |
| SVM (high vs. low)            | 3.90 (1.87–8.16) | < 0.001*          | 1.92 (1.10–3.34) | 0.022*            |
| Residual tumor (> 1 cm vs. ≤ 1 cm) | 1.47 (0.65–3.31) | 0.351             | 0.60 (0.34–1.06) | 0.077             |
| Grade (low vs. moderate)      | 0.53 (0.26–1.08) | 0.079             | 0.81 (0.45–1.46) | 0.494             |
| Stage (III C vs. IV)          | 0.56 (0.22–1.48) | 0.244             | 0.53 (0.19–1.53) | 0.242             |
| Age (> 55 y vs. ≤ 55 y)       | 1.71 (0.82–3.58) | 0.152             | 0.68 (0.39–1.17) | 0.164             |
| BRCA2                         | 1.75 (0.83–3.67) | 0.142             | 1.72 (0.91–3.22) | 0.093             |
| E-Cadherin                    | 0.68 (0.29–1.59) | 0.373             | 1.14 (0.66–1.95) | 0.642             |
| P53                           | 1.51 (0.73–3.12) | 0.263             | 1.41 (0.82–2.44) | 0.215             |
| BRCA1                         | 1.35 (0.61–2.95) | 0.458             | 1.32 (0.76–2.30) | 0.328             |
| p-AKT                         | 1.60 (0.78–3.30) | 0.199             | 1.10 (0.51–2.38) | 0.799             |
| DICER1                        | 0.65 (0.31–1.33) | 0.234             | 1.24 (0.72–2.15) | 0.434             |

HR = Hazord ratio; CI = confidence interval. *P < 0.05

Table 3: Association between SVM model and clinicopathological characteristics of ovarian cancer patients and PFS in testing patients of discovery cohort and in validation cohort

| Variables                      | Testing patients (n = 56) | Validation cohort (n = 95) |
|-------------------------------|----------------------------|----------------------------|
|                               | HR (95% CI) | P value | HR (95% CI) | P value |
| SVM (high vs. low)            | 2.92 (1.55–5.50) | 0.001* | 2.38 (1.45–3.91) | 0.001* |
| Residual tumor (> 1 cm vs. ≤ 1 cm) | 1.41 (0.74–2.70) | 0.299 | 0.45 (0.27–0.76) | 0.003* |
| Grade (low vs. moderate)      | 0.91 (0.49–1.69) | 0.774 | 0.78 (0.47–1.30) | 0.336 |
| Stage (III C vs. IV)          | 0.76 (0.36–1.58) | 0.464 | 0.70 (0.30–1.63) | 0.411 |
| Age (> 50 y vs. ≤ 50 y)       | 1.85 (1.01–3.39) | 0.047 | 0.82 (0.51–1.31) | 0.398 |
| BRCA2                         | 1.42 (0.78–2.59) | 0.256 | 1.23 (0.74–2.05) | 0.418 |
| E-Cadherin                    | 0.39 (0.20–0.75) | 0.005* | 1.32 (0.82–2.11) | 0.251 |
| P53                           | 1.51 (0.83–2.76) | 0.175 | 1.43 (0.89–2.29) | 0.142 |
| BRCA1                         | 2.61 (1.31–5.18) | 0.006* | 1.23 (0.76–1.99) | 0.407 |
| p-AKT                         | 1.59 (0.87–2.90) | 0.133 | 0.72 (0.42–1.25) | 0.239 |
| DICER1                        | 0.92 (0.51–1.68) | 0.797 | 0.99 (0.61–1.60) | 0.961 |

OR = Hazord ratio; CI = confidence interval. *P < 0.05
In summary, we have developed an SVM-based prognostic method to predict chemotherapy response in ovarian cancer patients; this method has high sensitivity and specificity, with high positive and negative predictive value. This HGSOC-SVM classifier predicts the chemoresponse, PFS and OS of patients better than any other clinical parameters. Although further validation is necessary, this prognostic strategy may allow clinicians to select the most appropriate therapies, apart from the standard paclitaxel and cisplatin approach, for individual ovarian cancer patients in advance, especially potentially chemoresistant patients.

METHODS

Patient selection

With the approval and support of the Ethics/Institutional Review Board of Tongji Hospital and Hubei Cancer Hospital (Wuhan, Hubei Province, China), HGSOC patients with FIGO stage III, or IV were identified. All patients were primary, biopsy-confirmed HGSOC who underwent debulking surgery and subsequent platinum/taxane-based chemotherapy. Informed consent was obtained from all patients. We enrolled two independent sets of HGSOC patients, including a discovery cohort of 156 patients diagnosed between October 2001 and July 2009 at Tongji hospital and a validation cohort of 95 patients with HGSOC diagnosed between October 2009 and December 2012 at Tongji Hospital and Hubei Cancer Hospital. Clinical features are listed in Table 1.

Follow-up information was updated in Jun 2014 through the patients' medical records and telephone based follow-up review. Chemotherapy resistance or sensitivity was defined as tumor relapse/progression within 6 months or 6 months after completion of prior platinum-based chemotherapy, respectively. Primary therapy response was defined as response evaluation criteria in solid tumors (RECIST). Progression-free survival (PFS) was calculated from time of surgery to time of progression or recurrence. Optimal debulking was defined as when residual tumors were ≤ 1 cm.

Tissue microarray construction and IHC

After review of HE-stained sections, three 1.5 mm cores were identified from the most representative areas of tumor tissue and re-embedded into tissue microarray blocks with a Manual Tissue Microarrayer (Beecher Instruments, Sun Prairie, WI, USA). Array blocks were sectioned to produce 4 μm sections.

Candidate protein markers used to build new prognostic classifiers in this study were selected from previous literatures, and involved in different aspects of chemotherapy resistance of HGSOC, including ABC transporter (LRP, MRP1, MRP2, ABCA1, SLC31A1),
microtubule assembly (TUBB3), DNA repair (ERCC1, BRCA1, Rad51, BRCA2, PARP1, 53BP1), cell cycle (Cyclin D1, CDK1, Ki67, Cyclin E1, P21WAF1, P27kip1), apoptosis (BAX, BCL-2, HSP27), epithelial-mesenchymal transition (EMT) (E-cadherin, Vimentin, transforming growth factor-β [TGF-β1], β-catenin), proto-oncogenes (MYC, FAK, HER2, EGFR, p-AKT), cancer stem cell marker (ALDH1, OCT4), ROS detoxification (SOD1, GSTP1), MicroRNA processing (Dicer1) and tumor suppressor (P53, PTEN) genes. IHC staining was performed according to standard procedures [27]. The information of these biomarkers is summarized in Supplementary Table 4. Appropriately selected positive-control samples were used according to the manufacturers’ instructions and included in each batch. For a negative-control samples were processed as per the standard protocol but without the primary antibodies from the dilution buffer.

IHC scoring

Tissue samples were scored manually using methods previously described [17]. Briefly, the aggregate score is the average of the score of tumor-cell staining multiplied by the score of staining intensity. Tumor-cell staining was assigned a score using a semi-quantitative five-category grading system: 0, no tumor-cell staining; 1, 1–10% tumor-cell staining; 2, 11–25% tumor-cell staining; 3, 26–50% tumor-cell staining; 4, 51–75% tumor-cell staining; and 5, > 75% tumor-cell staining. Staining intensity was assigned a score using a semi-quantitative four-category grading system: 0, no staining; 1, weak staining; 2, moderate staining; and 3, strong staining. Every core was assessed individually and the mean of the three readings was calculated for every case. The pattern of staining (cytoplasmic, membranous, nuclear) was also described in each case. Two trained histopathologists (Dr Su and Dr Li) blinded to clinical data scored all cases and a concordant score was obtained for 85.2% of the cases. A consensus score was recorded for the 14.8% of cases with a discordant score.

Introduction of SVM and details of experiments

SVM was used to predict whether a patient would have chemotherapy-resistant HGSOC based on clinicopathological features and immunomarkers. We performed a set of experiments in the discovery cohort of 156 HGSOC patients. And this cohort was further randomly subdivided into 100 patients for SVM training, and 56 for testing. To make an accurate assessment of the model, we re-enrolled an independent cohort of 95 patients in accordance with the modeling standards. These patients were input into the model as a double-blind test set to evaluate and calculate the sensitivity and specificity of the model. (Supplementary Figure 1)

Before training, all continuous data were preprocessed by standardizing to zero mean and unit variance. The same offset and scaling were applied to the test data. We adopted the SVM-recursive-feature-elimination (SVM-RFE) algorithm for feature selection. The radial basis function kernel was used, since our classification problem was nonlinear. During the training phase, 10-fold cross validation was used to determine the optimal values of the kernel parameter $a$ and the regularization parameter $C$ with a $10 \times 10$ grid search in the region $-10 < \log_{10} a < 10$ and $-10 < \log_{10} C < 10$, and step size of $\log_{10} 1$. This algorithm is performed 40 times, and each time, one feature subset is excluded. During the training, we evaluated the performance of SVM using 10-fold cross validation error. After the feature subset with the best 10-fold cross validation performance was selected, we predicted the labels of tested and validation samples and recorded the actual performance of the trained SVM models. The programs were coded with Matlab software (MathWorks, Natick, MA, USA).

Statistical analysis

Differences in patient characteristics between different groups were tested with Pearson $\chi^2$ test. To identify the association between all features with chemotherapy resistance, univariate Logistic regression was performed. Survival curves were estimated by the Kaplan-Meier method. Differences between survival curves were compared by the log-rank test. Univariate analyses of prognostic factors were performed with Cox proportional hazards regression modeling. In Logistic and Cox proportional hazards regression analysis, all immunological features were dichotomized according to cutoff values based on receiver operating characteristic (ROC) curve analysis. A significant difference was defined as a $P$ value of $\leq .05$ from a two-tailed test. All statistical analyses were performed with SPSS 16.0 for Windows (SPSS, Chicago, IL, USA).

ACKNOWLEDGMENTS AND FUNDINGS

This study is supported by the National Basic Research Program of China (973 Program, 2009CB521808), the National High Technology Research and and National Development Program of China (863 program, 2012AA02A507), and Nature and Science Foundation of China (81272859, 81230038, 81101962, 81402163, 81402164). We would like to acknowledge the contributions of Bing-Yu Sun for the data analysis and several useful comments to this project, and the contributions of Ian Campbell for the revision of this manuscript.
CONFLICTS OF INTEREST

The authors indicate no potential conflicts of interest.

REFERENCES

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA: a cancer journal for clinicians. 2010; 60:277–300.
2. Ovarian cancer, five-year stage-specific relative survival rates (2004–2008). Journal of the National Cancer Institute. 2011; 103:1287.
3. Kunos CA, Sill MW, Buekers TE, Walker JL, Schilder JM, Yamada SD, Wagggoner SE, Mohiuddin M, Fracasso PM. Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group. Gynecologic oncology. 2011; 120:224–228.
4. Spentzos D, Levine DA, Ramoni MF, Joseph M, Gu X, Boyd J, Libermann TA, Cannistra SA. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. Journal of clinical oncology. 2004; 22:4700–4710.
5. Hartmann LC, Lu KH, Linette GP, Cliby WA, Kalli KR, Gershenson D, Bast RC, Stee J, Iaichouk N, Smith DI, Ross JS, Hoersch S, Shridhar V, et al. Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clinical cancer research. 2005; 11:2149–2155.
6. Berchuck A, Iversen ES, Lancaster JM, Pittman J, Luo J, Lee P, Murphy S, Dressman HK, Febbo PG, West M, Nevinis JR, Marks JR. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clinical cancer research. 2005; 11:3686–3696.
7. Jazaeri AA, Awtrey GS, Chandramouli GV, Chuang YE, Khan J, Sotiriou C, Aprilekova O, Yee CJ, Zorn KK, Birrer MJ, Barrett JC, Boyd J. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clinical cancer research. 2005; 11:6300–6310.
8. Pascal LE, True LD, Campbell DS, Deutsch EW, Risk M, Coleman IM, Eichner LJ, Nelson PS, Liu AY. Correlation of mRNA and protein levels: cell type-specific gene expression of cluster designation antigens in the prostate. BMC genomics. 2008; 9:246.
9. Pyrri A, Kountourakis P, Yu Z, Papadimitriou C, Markakis S, Camp RL, Economonopoulos T, Dimopoulos MA. Analysis of p53 protein expression levels on ovarian cancer tissue microarray using automated quantitative analysis elucidates prognostic patient subsets. Annals of oncology. 2007; 18:709–715.
10. Lesnock JL, Darcy KM, Tian C, Deloia JA, Thrall MM, Zahn C, Armstrong DK, Birrer MJ, Krivak TC. BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study. British journal of cancer. 2013; 108:1231–1237.
11. Sun C, Li N, Ding D, Weng D, Meng L, Chen G, Ma D. The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis. PloS one. 2014; 9:e95285.
12. Zhang J, Guo X, Chang DY, Rosen DG, Mercado-Uribe I, Liu J. CD133 expression associated with poor prognosis in ovarian cancer. Modern pathology. 2012; 25:456–464.
13. Wei W, Mok SC, Oliva E, Kim SH, Mohapatra G, Birrer MJ. FGF18 as a prognostic and therapeutic biomarker in ovarian cancer. The Journal of clinical investigation. 2013; 123:4435–4448.
14. Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474:609–615.
15. Kang J, D'Andrea AD, Kozono D. A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy. Journal of the National Cancer Institute. 2012; 104:670–681.
16. Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, Yuan A, Cheng CL, Wang CH, Terng HJ, Kao SF, Chan WK, Li HN, Liu CC, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. The New England journal of medicine. 2007; 356:11–20.
17. Zhu ZH, Sun BY, Ma Y, Shao JY, Long H, Zhang X, Fu JH, Zhang LJ, Su XD, Wu QL, Ling P, Chen M, Xie ZM, et al. Three immunomarker support vector machines-based prognostic classifiers for stage IB non-small-cell lung cancer. Journal of clinical oncology. 2009; 27:1091–1099.
18. Li J, Chen Z, Tian L, Zhou C, He MY, Gao Y, Wang S, Zhou F, Shi S, Feng X, Sun N, Liu Z, Skogerboe G, et al. LncRNA profile study reveals a three-lncRNA signature associated with the survival of patients with oesophageal squamous cell carcinoma. Gut. 2014.
19. Kobel M, Reuss A, Bois S, Kommss S, Kommss F, Gao D, Kalogger SE, Huntsman DG, Gilks CB. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. The Journal of pathology. 2010; 222:191–198.
20. Venken PM, Kriege M, Hoogwerf D, Beuglin S, van der Burg ME, Hooning MJ, Berns EM, Jager A, Collee M, Burger CW, Seynaeve C. Chemosensitivity and outcome of ovarian cancer treated with platinum-based chemotherapy. Clinical cancer research. 2011; 123:4435–4448.
21. Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot CV, Zhao Y, Reynolds S, Cheng H, Rupaimoole R, Cogdell D, Nykter M, Broadus R, et al. Integrated Analyses Identify a Master MicroRNA Regulatory Network for the Mesenchymal Subtype in Serous Ovarian Cancer. Cancer cell. 2013; 23:186–199.
22. Bacic B, Haller H, Mrklic I, Kosta V, Caric A, Tomic S. Prognostic role of E-cadherin in patients with advanced serous ovarian cancer. Archives of gynecology and obstetrics. 2013; 287:1219–1224.

23. Faggad A, Budczies J, Tchernitsa O, Darb-Esfahani S, Sehouli J, Muller BM, Wirtz R, Chekerov R, Weichert W, Sinn B, Macha C, Elwali NE, Schafer R, et al. Prognostic significance of Dicer expression in ovarian cancer-link to global microRNA changes and oestrogen receptor expression. The Journal of pathology. 2010; 220:382–391.

24. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. The New England journal of medicine. 2008; 359:2641–2650.

25. Sun C, Li N, Yang Z, Zhou B, He Y, Weng D, Fang Y, Wu P, Chen P, Yang X, Ma D, Zhou J, Chen G. miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition. Journal of the National Cancer Institute. 2013; 105:1750–1758.

26. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005; 434:917–921.

27. Wang HY, Sun BY, Zhu ZH, Chang ET, To KF, Hwang JS, Jiang H, Kam MK, Chen G, Cheah SL, Lee M, Liu ZW, Chen J, et al. Eight-signature classifier for prediction of nasopharyngeal [corrected] carcinoma survival. Journal of clinical oncology. 2011; 29:4516–4525.